ABOUT US

 

Oxion Biologics is a biotechnology company based in Stockholm, Sweden. It was founded by a team of physician-scientists in 2021 with the goal of transforming and setting new standards in the management of autoimmune diseases and other immune-mediated conditions. Our lead asset OX118 is currently in pre-clinical development with the aim of entering clinical trials in 2024. 

​

This site is currently under construction. Stay tuned, and reach out to us under "Contact". 

​

​